As a university law lecturer, Nat is struggling to make ends meet. Her monthly salary of 33,000 baht is only a fraction of the cost of the super-expensive cancer drug she has been taking.In August ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive ...

The model of care the medical world is moving towards gives priority to patient-centred approaches and ensures every ...

Neladalkib (NVL-665). Nuvalent’s next-most advanced asset is NVL-655, an oral, brain-penetrant anaplastic lymphoma kinase [ALK] inhibitor for the treatment of ALK+ NSCLC – which accounts for ...

Kinase Inhibitors These drugs block certain enzymes that control cell growth, helping to keep lymphoma cells from growing. Targeted therapy drugs may have side effects. The types of side effects ...

for treating non-small-cell lung cancer (NSCLC) in adults whose cancer: is resectable (tumours 4 cm or over, or node positive) and has no epidermal growth factor receptor (EGFR) mutations or ...